Cell Cycle Arrest by Sabaek-san is Associated with induction of Cdk Inhibitor p21 in Human Lung Cancer A549 Cells

사백산에 의한 인체 폐암세포의 G1기 성장억제기전에 관한 연구

  • Kang Byong Ryeung (Department of Internal Medicine, Dongeui University and Research Institute of Oriental Medicine) ;
  • Oh Chang Sun (Department of Internal Medicine, Dongeui University and Research Institute of Oriental Medicine) ;
  • Lee Jae Hun (Department of Biochemistry, College of Oriental Medicine, Dongeui University and Research Institute of Oriental Medicine) ;
  • Choi Yung Hyun (Department of Biochemistry, College of Oriental Medicine, Dongeui University and Research Institute of Oriental Medicine) ;
  • Park Dong Il (Department of Internal Medicine, Dongeui University and Research Institute of Oriental Medicine)
  • 강병령 (동의대학교 한의과대학 폐계내과학교실) ;
  • 오창선 (동의대학교 한의과대학 폐계내과학교실) ;
  • 이재훈 (동의대학교 한의과대학 생화학교실 및 한의학연구소) ;
  • 최영현 (동의대학교 한의과대학 생화학교실 및 한의학연구소) ;
  • 박동일 (동의대학교 한의과대학 폐계내과학교실)
  • Published : 2002.12.01

Abstract

We investigated the effects of Sabaek-san (SBS) water extract on the cell proliferation of human lung carcinoma A549 cells. SBS treatment resulted in the inhibition of cell proliferation in a concentration-dependent manner. This anti-proliferative effect of A549 cells by SBS treatment was associated with morphological changes such as membrane shrinking and cell rounding up. DNA flow cytometric histograms showed that population of G1 phase of the cell cycle was increased by SBS treatment in a concentration-dependent manner. SBS treatment induced a marked accumulation of tumor suppressor p53 and a concomitant induction of cyclin-dependent kinase (Cdk) inhibitor p21WAF1/CIP, which appears to be transcriptionally upregulated and is p53 dependent. In addition, SBS treatment resulted in down-regulation of cyclooxygenase-2 (COX-2) as determined by RT-PCR analysis. The present results indicated that SBS-induced inhibition of lung cancer cell proliferation is associated with the blockage of G1/S progression the induction of apoptosis.

Keywords

References

  1. 東醫腫瘍學 최승훈
  2. 2001년 사망원인통계결과 통계청
  3. 인간생명과학 박재갑
  4. 임상호흡기학 한용철
  5. 中醫學 臨床病理 北京中醫學院(編)
  6. 내과학회지 v.16 瀉白散과 瀉白散訶黎勒이 呼吸器系에 미치는 影響. 이순호;한상환
  7. 내과학회지 v.16 肺實證에 응용된 瀉白散의 文獻的 考察 이순호;한상환
  8. 내과학회지 v.11 瀉白散이 Compound 48/80에 의하여 유도된 Anaphylatic Shock와 피하반응에 미치는 影響 김민호;한상환;전병득
  9. 東醫寶鑑 許浚
  10. Int. J. Oncol. v.21 Tetrandrine- induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells. Lee, J,H.;Kang, G.H.;Kim, K.C.;Kim, K.M.;Park, D.I.;Choi, B.T.;Kang, H.S.;Lee, Y.T.;Choi, Y.H.
  11. Exp. Mol. Med. v.33 Research technics for the cell cycle study Choi, Y.H.
  12. J. Biol. Chem. v.272 Regulation of cyclin D1 by calpain protease. Choi, Y.H.;Lee, S.J.;Nguyen, P.;Jang, J.S.;Lee, J.;Wu, M.L.;Takano, E.;Maki, M.;Henkart, P.A.;Trepel, J.B.
  13. 漢藥臨床應用 李尙仁
  14. 本草綱目 李時珍
  15. 臨床本草學 辛民敎
  16. Cancer Res v.60 The Pezcoller lecture: cancer cell cycles revisited. Sherr, C.J.
  17. Cell v.81 The retinoblastoma protein and cell cycle control. Weinberg, R.A.
  18. Mol. Cell. Biol. v.14 D-type cyclin-dependent kinase activity in mammalian cells. Matsushime, H.;Quelle, D.E.;Shurtleff, S.A.;Shibuya, M.;Sherr, C.J.; Kato, J.Y.
  19. Mol. Cell. Biol. v.14 Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Meyerson, M.;Harlow, E.
  20. Science v.257 Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Koff, A.;Giordano, A.;Desai, D.;Yamashita, K.;Harper, J.W.;Elledge, S.;Nishimoto, T.;Morgan, D.O.;Franza, B.R.;Roberts, J.M.
  21. Science v.259 Cyclin-dependent regulation of G1 in mammalian fibroblasts. Ohtsubo, M.;Roberts, J.M.
  22. Cell v.67 Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Girard, F.;Strausfeld, U.;Fernandez, A.;Lamb, N.J.
  23. Nature v.354 Role for cyclin A in the dependence of mitosis on completion of DNA replication. Walker, D.H.;Maller, J.L.
  24. EMBO J. v.15 The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. Brandeis, M.;Hunt, T.
  25. Curr. Opin. Cell Biol. v.6 Cdk inhibitors: on the threshold of checkpoints and development. Elledge, S.J.;Harper, J.W.
  26. Nature v.374 Principles of CDK regulation. Morgan, D.O.
  27. Nature v.366 Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Gu, Y.;Turck, C.W.;Morgan, D.O.
  28. Cell v.75 The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Harper, J.W.;Adami, G.R.;Wei, N.;Keyomarsi, K.;Elledge, S.J.
  29. Cell v.75 WAF1 a potential mediator of p53 tumor suppression. El-Deiry, W.S.;Tokino, T.;Velculesco, V.E.;Levy, D.B.;Parsons, R.; Trent, J.M.;Lin, D.;Mercer, E.W.;Kinzler, K.W.;Vogelstain, B.
  30. Nature v.366 p21 is a universal inhibitor of cyclin kinases. Xiong, Y.;Hannon, G.;Zhang, H.;Casso, D.;Kobayashi, R.;Beach, D.
  31. Cancer Res. v.54 WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. El-Deiry, W.S.;Harper, J.W.;O'Connor, P.M.;Velculescu, V.E.; Canman, C.E.;Jackman, J.;Pietenpol, J.A.;Burrell, M.;Hill, D.E.;Wang, Y.; Wiman, K.G.;Mercer, W.E.;Kastan, M.B.;Kohn, K.W.;Elledge, S.J.; Kinzler, K.W.;Vogelstain, B.
  32. Annu. Rev. Med. v.53 Cyclooxygenase-2: a therapeutic target. Turini, M.E.;DuBois, R.N.
  33. Best Pract. Res. Clin. Gastroenterol. v.15 COX-2 inhibition and prevention of cancer. Giercksky, K.E.
  34. Int. J. Cancer v.94 Is COX-2 inhibition a panacea for cancer prevention? Vainio, H.
  35. J. Cancer Res. Clin. Oncol. v.127 Cyclooxygenase-2: a novel target for cancer chemotherapy? Dempke, W.;Rie, C.;Grothey, A.;Schmoll, H.J.
  36. Mutat. Res. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytoche- micals: down-regulation of COX-2 and iNOS through suppression of NF-$\kappa$B activation. Surh, Y.J.;Chun, K.S.;Cha, H.H.;Han, S.S.;Keum, Y.S.;Park, K.K.; Lee, S.S.
  37. Int. J. Mol. Med. v.2 Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Chiarugi, V.;Magnelli, L.;Gallo, O.
  38. Lab. Invest. v.79 Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Sawaoka, H.;Tsuji, S.;Tsujii, M.;Gunawan, E.S.;Sasaki, Y.;Kawano, S.;Hori, M.
  39. J. Natl. Cancer Inst. v.94 Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. Thun, M.J.;Henley, S.J.;Patrono, C.
  40. J. Clin. Invest. v.107 Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. Yamamoto, Y.;Gaynor, R.B.